Related references
Note: Only part of the references are listed.Analysis of predictors of response to ruxolitinib in patients with myelofibrosis in the phase 3b expanded-access JUMP study
Vikas Gupta et al.
LEUKEMIA & LYMPHOMA (2021)
Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts
Haifa Kathrin Al-Ali et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial
Stephen T. Oh et al.
BLOOD ADVANCES (2020)
Myeloablative and Reduced-Intensity Conditioned Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis: A Retrospective Study by the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation
Donal McLornan et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
Advances in potential treatment options for myeloproliferative neoplasm associated myelofibrosis
Prithviraj Bose
EXPERT OPINION ON ORPHAN DRUGS (2019)
Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet
Tiziano Barbuil et al.
LEUKEMIA (2018)
The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion
Tiziano Barbui et al.
BLOOD CANCER JOURNAL (2018)
Primary myelofibrosis: 2019 update on diagnosis, risk-stratification and management
Ayalew Tefferi
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Anemia in myelofibrosis-prevalence, the U2AF1 connection, new treatments
Ayalew Tefferi
BLOOD CANCER JOURNAL (2017)
Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis
Francesca Palandri et al.
ONCOTARGET (2017)
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Daniel A. Arber et al.
BLOOD (2016)
Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial
Haifa Kathrin Al-Ali et al.
HAEMATOLOGICA (2016)
Impact of ruxolitinib treatment on the hemoglobin dynamics and the negative prognosis of anemia in patients with myelofibrosis
Haifa Kathrin Al-Ali et al.
LEUKEMIA & LYMPHOMA (2016)
Alleviating anemia and thrombocytopenia in myelofibrosis patients
Francisco Cervantes et al.
EXPERT REVIEW OF HEMATOLOGY (2016)
Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial
Haifa Kathrin Al-Ali et al.
HAEMATOLOGICA (2016)
Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST Trial
Adam J. Mead et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis
Mary Frances McMullin et al.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2015)
Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report
Ayalew Tefferi et al.
BLOOD (2013)
Practical management of patients with myelofibrosis receiving ruxolitinib
Claire Harrison et al.
EXPERT REVIEW OF HEMATOLOGY (2013)
A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
Srdan Verstovsek et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
Claire Harrison et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status
Naseema Gangat et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Outcome of Transplantation for Myelofibrosis
Karen K. Ballen et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2010)
A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)
Francesco Passamonti et al.
BLOOD (2010)
Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis.
Srdan Verstovsek et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Primary Myelofibrosis: Update on Definition, Pathogenesis, and Treatment
Omar I. Abdel-Wahab et al.
ANNUAL REVIEW OF MEDICINE (2009)
New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment
Francisco Cervantes et al.
BLOOD (2009)
Janus kinases in immune cell signaling
Kamran Ghoreschi et al.
IMMUNOLOGICAL REVIEWS (2009)
Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the international working group for myelofibrosis research and treatment
G. Barosi et al.
LEUKEMIA (2008)
The burden of fatigue and quality of life in myeloproliferative disorders (MPDs) - An international internet-based survey of 1179 MPD patients
Ruben A. Mesa et al.
CANCER (2007)
A gain-of-function mutation of JAK2 in myeloproliferative disorders
R Kralovics et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
EJ Baxter et al.
LANCET (2005)
Share Paper
